Medtronic Acquires SPR Therapeutics to Expand Pain Intervention Offerings
Medtronic (MDT) has agreed to acquire SPR Therapeutics in a $650 million deal, aiming to enhance its Neuromodulation portfolio with temporary peripheral nerve stimulation technology. The acquisition is expected to close by the first half of Medtronic’s Fiscal Year 2027 and will expand access to minimally invasive pain relief solutions.
Tickers: $MDT